Dopamine Reuptake Inhibitors of Cocaine Abuse - 1

This study has been terminated.

First Received on September 20, 1999. Last Updated on December 22, 2008 History of Changes

Sponsor:	National Institute on Drug Abuse (NIDA)
Collaborator:	VA Connecticut Healthcare System
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000276

Purpose

The purpose of this study is to evaluate dopamine reuptake inhibitors for cocaine abuse.

Condition	Intervention	Phase
Cocaine-Related Disorders	Drug: Bupropion	Phase I

Study Type:	Interventional
Study Design:	Primary Purpose: Treatment
Official Title:	Dopamine Reuptake Inhibitors of Cocaine Abuse

Resource links provided by NLM:

Drug Information available for: Dopamine Cocaine hydrochloride Dopamine hydrochloride Bupropion hydrochloride Bupropion

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Side effects
Cocaine effects

Estimated Enrollment:

Eligibility

Ages Eligible for Study:	18 Years to 45 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000276

Locations

United States, Connecticut
VA Connecticut Healthcare System
New Haven, Connecticut, United States, 06519

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

VA Connecticut Healthcare System

Investigators

Principal Investigator:

Thomas R Kosten, M.D.

VA Connecticut Healthcare System

More Information

No publications provided

Responsible Party:	Thomas R Kosten, M.D., Yale University School of Medicine / VA Connecticut Healthcare System
ClinicalTrials.gov Identifier:	NCT00000276 History of Changes
Other Study ID Numbers:	NIDA-09250-1, P50-09250-1
Study First Received:	September 20, 1999
Last Updated:	December 22, 2008
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Cocaine-Related Disorders
Substance-Related Disorders
Mental Disorders
Dopamine
Bupropion
Dopamine Uptake Inhibitors
Cardiotonic Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Sympathomimetics
Autonomic Agents

Peripheral Nervous System Agents
Physiological Effects of Drugs
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Protective Agents
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Central Nervous System Agents
Neurotransmitter Uptake Inhibitors

ClinicalTrials.gov processed this record on February 12, 2012